Ar­row­head spot­lights key pan­cre­ati­tis fig­ures from Phase 3 lipid dis­ease study to dif­fer­en­ti­ate it­self from Io­n­is

Ar­row­head Phar­ma­ceu­ti­cals has un­veiled high­ly an­tic­i­pat­ed pan­cre­ati­tis re­sults from a late-phase tri­al of ploza­sir­an for a rare lipid dis­or­der, sev­er­al months af­ter re­port­ing topline da­ta …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER